Follow the Pundits
Tag: featured-hedge-funds
Buffett Steps Down as CEO — Should You Step Away from Berkshire?
Buffett steps aside as CEO. The cash pile is massive. The machine still hums. Should long-term investors stay the course with Berkshire Hathaway?
Michael Burry Has 38% of His Portfolio in Lululemon: Time To Wear The Pants?
Michael Burry just made Lululemon a top portfolio holding. With valuation down, buybacks up, and shorts watching — is it time to wear the pants?
Insiders Are Buying Under Armour: Strong Suit or Skip the Knight-Mare?
Under Armour trades over 90% below its all-time high—but insiders are buying aggressively. Is this a rare turnaround opportunity or a classic value trap? Let’s break it down.
Baker Bros Are Bullish — Can Kodiak Kill the Bears?
When the sharpest biotech investors on the planet deploy $60 million, it’s worth paying attention. Kodiak Sciences is a high-risk, high-reward retinal biotech with late-stage trials, real institutional backing, and binary outcomes ahead. Fun, factual, and unapologetically speculative.
Biotech Investor Extraordinaire Baker Bros Adds to Its Massive Stake in Kymera. Should You Buy In?
Baker Bros — the Warren Buffetts of biotech — just super-sized their Kymera (KYMR) position. With Fast Track designation, jaw-dropping STAT6 trial results, and a pioneering protein-degradation platform, is KYMR becoming the next biotech legend?
Could MGM Suddenly Stand for “My Great Money-Maker?”
Barry Diller is doubling down, insiders are buying, and MGM’s digital arm is gaining traction. Is the casino giant quietly becoming a global money machine again?
New CEO and Activist Corvex’s Keith Meister Buy Vestis; Expect Profits or Casual Tees?
A new CEO with UPS DNA, millions in insider buys, and activist hedge fund Corvex circling… Vestis stock checks many contrarian boxes. But high leverage and a slow turnaround mean this is not for the faint of heart. 👕📈
Paulson & Co Keeps Adding to His Bausch Health Stake: Should Investors See Eye to Eye With Him?
Billionaire John Paulson now owns nearly 19% of Bausch Health — and he keeps buying. With improving earnings, low valuation, and high risk, BHC may be a speculative value play worth watching.
Biotech Venture Capital Firm Casdin Keeps Buying Standard BioTools Shares — Time To Invest, Or Time To Label This “Highly Experimental”?
Casdin Capital just scooped up over a million shares of Standard BioTools — again. With strong tech, big cash coming from Illumina, and a major restructuring underway, is this small-cap biotech tools maker a deep-value setup or just another “high-risk, high-lab-cost” gamble? Here’s what’s really going on.